ライフサイエンスコーパス: topical corticosteroid

1 early, but not late, application of a potent topical corticosteroid.

2 patients because of self-discontinuation of topical corticosteroid.

3 nd subsequent mild uveitis was responsive to topical corticosteroids.

4 hese adverse effects are easily managed with topical corticosteroids.

5 e response associated with keratitis include topical corticosteroids.

6 rm, resistant to systemic antihistamines and topical corticosteroids.

7 y retinal lesions and exhibit no response to topical corticosteroids.

8 n eliminating exposure to food allergens, or topical corticosteroids.

9 At baseline, 56 eyes (75%) were on topical corticosteroids.

10 cal corticosteroids, and 315 to placebo plus topical corticosteroids.

11 calcineurin inhibitors where inadvisable for topical corticosteroids.

12 in this series had an inadequate response to topical corticosteroids.

13 ipants said that they need reassurance about topical corticosteroids.

14 o steroid group) resolved with resumption of topical corticosteroids.

15 lar GVHD without the hypertensive effects of topical corticosteroids.

16 s than in patients treated with placebo plus topical corticosteroids.

17 o assess patients' worries and beliefs about topical corticosteroids.

18 ts were treated with aggressive systemic and topical corticosteroids.

19 ive retreatment achieved using rituximab and topical corticosteroids.

20 abetic and diabetic patients, as compared to topical corticosteroids.

21 were randomly assigned to dupilumab qw plus topical corticosteroids, 106 to dupilumab q2w plus topic

22 83%) patients who received dupilumab qw plus topical corticosteroids, 97 (88%) patients who received

23 6, more patients who received dupilumab plus topical corticosteroids achieved the coprimary endpoints

24 rneal erosions, such as oral doxycycline and topical corticosteroid, alcohol delamination, substance

25 Use of superpotent topical corticosteroids alone (by 100 patients [83.3%])

26 ainst BP230 confirmed the use of superpotent topical corticosteroids alone as a reference BP treatmen

27 n of the suspected agent in conjunction with topical corticosteroid and cycloplegic therapy.

28 ve patients were treated preoperatively with topical corticosteroids and anti-CMV treatment (oral val

29 Topical corticosteroids and calcineurin inhibitors are w

30 inhibitors; new topical combinations such as topical corticosteroids and calcipotriene; and new techn

31 ing adalimumab therapy since they respond to topical corticosteroids and do not necessarily prompt th

32 A combination of topical corticosteroids and NSAIDs significantly reduced

33 udy (HEDS) I showed a significant benefit of topical corticosteroids and oral acyclovir for stromal k

34 tment regimen that includes a combination of topical corticosteroids and topical cidofovir as a desir

35 g atopic dermatitis (AD) was still primarily topical corticosteroids and, for more severe disease, sy

36 drugs, but severe cases need treatment with topical corticosteroids and/or immunotherapy (SCIT).

37 Thirty-seven cases (66%) were treated with topical corticosteroids and/or observation alone.

38 (31.7%), respectively, made comparisons with topical corticosteroids, and 25 (64.1%) and 15 (36.6%),

39 l corticosteroids, 106 to dupilumab q2w plus topical corticosteroids, and 315 to placebo plus topical

40 Eighteen patients were treated with topical corticosteroids, and only 1 patient required dis

41 nt received a combination of antihistamines, topical corticosteroids, and thick emollient creams, ren

42 Of note, superpotent topical corticosteroid application quickly and markedly

43 Topical corticosteroids are indicated for pregnant women

44 Topical corticosteroids are the current first-line thera

45 Patients treated with topical corticosteroids as adjunctive therapy within 2 t

46 eatment received rituximab with high-potency topical corticosteroids as first-line treatment.

47 The use of topical corticosteroids as local therapy for anterior uv

48 The outcomes of patients treated with topical corticosteroids before diagnosis of AK were comp

49 AK were compared with those not treated with topical corticosteroids before diagnosis.

50 inystalia yohimbe); potentiation of oral and topical corticosteroids by liquorice (Glycyrrhiza glabra

51 The combination of rituximab and topical corticosteroids could be considered in mild to s

52 Topical corticosteroids could be tapered, stopped, or re

53 Topical corticosteroids dispensed during pregnancy.

54 oral corticosteroids to less than 10 mg/d or topical corticosteroid drops to less than 2 drops daily,

55 wever, maternal use of potent to very potent topical corticosteroids, especially when the cumulative

56 Continued once-per-day use of a topical corticosteroid, even a weak one, was protective

57 he dispensed amount of potent or very potent topical corticosteroids exceeded 300 g during the entire

58 No associations of maternal topical corticosteroid exposure with orofacial cleft, lo

59 ssuringly showed no associations of maternal topical corticosteroid exposure with orofacial cleft, pr

60 ight seems to correlate with the quantity of topical corticosteroid exposure.

61 aline and the other treated with saline plus topical corticosteroid eye drops (0.5% loteprednol etabo

62 Respondents reported treatment with topical corticosteroids for 2 to 8 weeks (46/86, 53 %),

63 tive effectiveness trials such as the use of topical corticosteroids for pemphigoid may have played a

64 Active comparators (mild topical corticosteroids for pimecrolimus and moderate to

65 oids for pimecrolimus and moderate to potent topical corticosteroids for tacrolimus) are best placed

66 the risk benefit associated with the use of topical corticosteroids for the management of inflammato

67 Her findings resolved with observation and topical corticosteroids for uveitis.

68 rgery when compared directly with placebo or topical corticosteroid formulations with limited intraoc

69 anterior chamber cells of >/=1+ or requiring topical corticosteroid >/=3 times daily, and who were on

70 To date, therapy with topical corticosteroids has been shown to reverse esopha

71 There may be a benefit with adjunctive topical corticosteroids if application occurs earlier in

72 excisional biopsy in 5 patients (5/9, 56%), topical corticosteroids in 2 patients (2/9, 22%), and ob

73 topical corticosteroids versus placebo with topical corticosteroids in adults with moderate-to-sever

74 Compared with a wide potency range of topical corticosteroids in clinical formulations, 0.3% a

75 ed the odds of developing CME as compared to topical corticosteroids in nondiabetic (odds ratio [OR]

76 ed the odds of developing CME as compared to topical corticosteroids in nondiabetic (OR 0.21; 95% CI

77 Long-term use of topical corticosteroids in skin inflammation poses risks

78 is of herpes keratitis and before the use of topical corticosteroids in the therapy of any indolent k

79 d the odds of developing CME, as compared to topical corticosteroids, in nondiabetic and mixed popula

80 ions increased a mean of 195%, and prices of topical corticosteroids increased a mean of 290% during

81 e evaluated whether treatment with swallowed topical corticosteroids is able to reduce the risk of oc

82 studies have shown that medical therapy with topical corticosteroids is effective in treating EoE, th

83 ion, even using higher doses of systemic and topical corticosteroids, is of importance in preventing

84 Localised adjuvant potent topical corticosteroids (<30 g per week) were permitted

85 h comparisons with active treatments such as topical corticosteroids might have been included or avoi

86 elemental diet, 6-food elimination diet, or topical corticosteroids (n = 6 per group).

87 nce found no associations of maternal use of topical corticosteroids of any potency with mode of deli

88 ce for anogenital lichen sclerosus is potent topical corticosteroid ointment for a limited time.

89 Treatment with potent topical corticosteroids or methotrexate sodium led to re

90 s by using proactive approaches (with either topical corticosteroids or topical calcineurin inhibitor

91 12% [39 patients] who received placebo plus topical corticosteroids; p<0.0001) and EASI-75 (64% [204

92 More than half of the participants believed topical corticosteroids pass into bloodstream, damage th

93 on to endophthalmitis include patients using topical corticosteroids, patients with fungal keratitis,

94 volves skin directed therapies which include topical corticosteroids, phototherapy (psoralen with UVA

95 l cases were treated with intensive, potent, topical corticosteroids: prednisolone acetate 1% eye dro

96 Topical corticosteroids, preferably those with reduced s

97 % [125 patients] who received dupilumab plus topical corticosteroids qw and 39% [41 patients] who rec

98 Are topical corticosteroids safe for use in pregnancy?

99 ect the treatment of isolated keratitis, (2) topical corticosteroids should not be used for treating

100 Treatment of EoE with swallowed topical corticosteroids significantly reduces the risk f

101 w treatment options; EoE can be treated with topical corticosteroids, such as fluticasone and budeson

102 Topical corticosteroid (TCS) phobia refers to the negati

103 from children (n = 32) with EoE treated with topical corticosteroids (TCSs) over 10 years (mean, 4.5

104 y associated with bolus impaction: swallowed topical corticosteroid therapy (OR 0.411, 95%-CI 0.203-0

105 iate logistic regression modeling: swallowed topical corticosteroid therapy (OR 0.503, 95%-CI 0.255-0

106 rts daily high-volume saline irrigation with topical corticosteroid therapy as a first-line therapy f

107 The second case outlines the use of topical corticosteroid therapy as an adjunct to non-surg

108 Topical corticosteroid therapy improved overall symptom

109 Adjunctive topical corticosteroid therapy may be associated with im

110 art of AAT and subsequently at the time that topical corticosteroid therapy was initiated.

111 Intensified topical corticosteroid therapy was started immediately a

112 Symptoms and infiltrates regressed after topical corticosteroid therapy, but recurred after each

113 s reassurance that the potential benefits of topical corticosteroid therapy, for treating pain and di

114 erved in all patients, and none responded to topical corticosteroid therapy.

115 grade II dermatitis that was unresponsive to topical corticosteroid therapy.

116 The patient was successfully treated using topical corticosteroid therapy.

117 flammation (n = 1), which resolved following topical corticosteroid therapy.

118 Despite prompt treatment with topical corticosteroids, these 3 patients eventually req

119 ds, especially when the cumulative dosage of topical corticosteroids throughout the pregnancy is very

120 of participants were anxious about applying topical corticosteroids to certain zones like eyelids, a

121 hoose whether to stop or continue once-daily topical corticosteroids to maximize compliance.

122 trial that overall found no effect of adding topical corticosteroids to topical moxifloxacin hydrochl

123 Medical interventions included topical corticosteroids, topical cyclosporine, topical v

124 mmon in patients treated with dupilumab plus topical corticosteroids-treated patients than in patient

125 INTERPRETATION: Dupilumab added to standard topical corticosteroid treatment for 1 year improved ato

126 led trial assessing the effect of adjunctive topical corticosteroid treatment on outcomes in bacteria

127 After 8 days of topical corticosteroid treatment visual acuity was worse

128 The mean duration of topical corticosteroid treatment was 45 +/- 28 days (med

129 i-Programmed cells Death-1 was stopped and a topical corticosteroid treatment was administrated.

130 using Huber robust regression, adjusting for topical corticosteroid treatment.

131 for a total of 6 doses in addition to daily topical corticosteroid treatment.

132 mized trial to compare nebulized and viscous topical corticosteroid treatments for eosinophilic esoph

133 al graft (20.6% vs 0%, P = .0012), and prior topical corticosteroid use (23.5% vs 5%, P = .019).

134 esenting visual acuity worse than 20/40, and topical corticosteroid use (in a dose-response relations

135 ds in the last 3 months (aHR, 2.23); current topical corticosteroid use [>/=8x/day vs. none] (aHR, 2.

136 ficantly associated with worse outcomes were topical corticosteroid use before the start of AAT (OR,

137 Topical corticosteroid use could often be reduced or sto

138 , sex, prior oral corticosteroid dose, prior topical corticosteroid use, and concomitant immunosuppre

139 oral proximity to diagnosis of arthritis and topical corticosteroid use.

140 and safety of dupilumab with medium-potency topical corticosteroids versus placebo with topical cort

141 -B, when used in combination with psoralens, topical corticosteroids, vitamin D analogues, fluorourac

142 41 patients] who received dupilumab q2w plus topical corticosteroids vs 12% [39 patients] who receive

143 We assess the effect of topical corticosteroids (vs placebo) on 3-month best spe

144 oxifloxacin alone, adjunctive treatment with topical corticosteroids was associated with significantl

145 tified in which pimecrolimus, tacrolimus, or topical corticosteroids were compared with another inter

146 atopic dermatitis and inadequate response to topical corticosteroids were enrolled at 161 hospitals,

147 scleritis and hypopyon at the start of AAT, topical corticosteroids were not associated with worse o

148 Treatments with systemic and topical corticosteroids were not significant risk factor

149 Oral prednisone and topical corticosteroids were tapered.

150 Current clinical treatments use topical corticosteroids, which broadly and transiently s

151 nts with recurrent nasal polyposis receiving topical corticosteroids who required surgery, mepolizuma

152 r disease limited to the nails, high-potency topical corticosteroids with or without calcipotriol are

153 All three groups were given concomitant topical corticosteroids with or without topical calcineu

154 ll patients had been treated previously with topical corticosteroids without any improvement and also